News & Blog

Author Archives: Tom Halkin

National Brain Tumor Society Statement on New Biden-Harris Cancer Moonshot Goals

National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, was honored to represent the millions of Americans impacted by brain tumors every year at a White House event to reignite the Cancer Moonshot.  The following is a statement from NBTS chief executive officer, David Arons, on today’s announcement. […]

NBTS Brain Tumor Clinical Trials Report: Q4 2021

It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started […]

Widely-available Drug May Benefit Glioblastoma Treatment

Based on data from NBTS’s Defeat GBM Research Collaborative and with support from the Sharpe family, Dr. Paul Mischel (Stanford University) and his laboratory team found that the antidepressant drug, fluoxetine (common brand name: Prozac), potently targets tumor metabolism and inhibits epidermal growth factor (EGFR) signaling, triggering the killing of glioblastoma (GBM) cells. Dr. Mischel’s […]

Share